跳至主要内容
临床试验/NL-OMON25676
NL-OMON25676尚未招募不适用

Administration of immune checkpoint inhibitors through an elastomeric pump. A patient preference study and cost analysis.

Erasmus MC0 个研究点目标入组 390 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
发起方
Erasmus MC
入组人数
390

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Age =18 years;
  • - Able and willing to give written informed consent;
  • - Planned treatment with Nivolumab or Pembrolizumab monotherapy (in case of Nivolumab with or without prior
  • treatment with Nivolumab/Ipilimumab) for any EMA approved indication and with any dose;
  • - Adequate Dutch language proficiency (at least proficiency level C1)
  • - At least 3 prior cycles of Nivolumab or Pembrolizumab therapy
  • - At least 4 remaining cycles of Nivolumab or Pembrolizumab monotherapy after inclusion in the study.

排除标准

  • - Prior infusion related reactions to Nivolumab or Pembrolizumab (any grade).

研究者

发起方
Erasmus MC

相似试验